MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Sep 4, 2025--
Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B financing co-led by Arboretum Ventures and Hatteras Venture Partners. Proceeds will advance BOOM-IBD2, the first pivotal trial of implantable neuromodulation in inflammatory bowel disease, with an initial focus on ulcerative colitis. The trial is currently enrolling patients at leading medical centers across the U.S. (NCT06571669).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250904154790/en/
Ulcerative colitis, the most common form of IBD, is a chronic autoimmune disease affecting millions of people in the U.S. and Europe, and there are no device-based options in this field. Boomerang is evaluating whether a small implanted device that delivers gentle nerve stimulation, known as sacral neuromodulation, can help address symptom burden in ulcerative colitis. The company completed a 40-patient feasibility study in Crohn's disease and ulcerative colitis, and those results informed the design of BOOM-IBD2, its pivotal trial in ulcerative colitis. Sacral neuromodulation itself has a long safety record in other conditions, with more than 500,000 procedures performed worldwide.
"Ulcerative colitis patients struggle with symptoms that profoundly affect their daily lives," said Heather Simonsen, CEO of Boomerang Medical. "Our pivotal trial asks a simple but critical question: can this therapy meaningfully reduce symptom burden and improve quality of life for people living with ulcerative colitis? With the continued support of our investors, we're pursuing that answer for patients and their physicians."
"There is a clear and significant unmet need for new approaches to help patients suffering from the debilitating symptoms of ulcerative colitis," said Tom Shehab, MD, gastroenterologist, Managing Partner at Arboretum Ventures and member of the Board of Directors. "We are impressed with the Boomerang team and their rigorous approach to clinical development. We are confident this financing will position them well to complete their pivotal trial and move this promising therapy forward."
The Crohn's & Colitis Foundation named Boomerang Medical its "Emerging Leader in IBD"—the first medical device company to receive this recognition.
For more information about BOOM-IBD2 or to refer patients, physicians can visit ClinicalTrials.gov: NCT06571669.
About Boomerang Medical Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. Headquartered on the campus of El Camino Hospital in Mountain View, California, the company is a Company-In-Residence at Fogarty Innovation, the only healthcare-focused incubator of its kind in the U.S. Boomerang was the first medical device company recognized as "Emerging Leader in IBD" by the Crohn's & Colitis Foundation. For more information, visit www.boomerangmedical.com.
About Arboretum Ventures Founded in 2002, Arboretum Ventures manages over $1 billion in healthcare venture capital from its Ann Arbor, Michigan base. The firm focuses on medical devices and healthcare services that address significant unmet needs. Portfolio companies have achieved multiple strategic exits to industry leaders. Visit www.arboretumvc.com.
About Hatteras Venture Partners Founded in 2000, Hatteras Venture Partners has invested in over 100 healthcare companies from its Research Triangle Park, North Carolina headquarters. The firm recently raised over $200 million across two healthcare-focused funds. Visit www.hatterasvp.com.
Heather Simonsen, CEO, Boomerang Medical
WASHINGTON (AP) — President Donald Trump on Thursday threatened Canada with a 50% tariff on any aircraft sold in the U.S., the latest salvo in his trade war with America’s northern neighbor as his feud with Prime Minister Mark Carney expands.
Trump’s threat posted on social media came after he threatened over the weekend to impose a 100% tariff on goods imported from Canada if it went forward with a planned trade deal with China. But Trump’s threat did not come with any details about when he would impose the import taxes, as Canada had already struck a deal.
In Trump’s latest threat, the Republican president said he was retaliating against Canada for refusing to certify jets from Savannah, Georgia-based Gulfstream Aerospace.
Trump said the U.S., in return, would decertify all Canadian aircraft, including planes from its largest aircraft maker, Bombardier. “If, for any reason, this situation is not immediately corrected, I am going to charge Canada a 50% Tariff on any and all Aircraft sold into the United States of America,” Trump said in his post.
Trump said he is “hereby decertifying" the Bombardier Global Express business jets. There are 150 Global Express aircraft in service registered in the U.S., operated by 115 operators, according to Cirium, the aviation analytics company.
Spokespeople for Bombardier and Canada’s transport minister didn’t immediately respond to messages seeking comment Thursday evening.
The U.S. Commerce Department previously put duties on a Bombardier commercial passenger jet in 2017 during the first Trump administration, charging that the Canadian company was selling the planes in America below cost. The U.S. said then that the Montreal-based Bombardier used unfair government subsidies to sell jets at artificially low prices.
The U.S. International Trade Commission in Washington later ruled that Bombardier did not injure U.S. industry.
Bombardier has since concentrated on the business and private jet market. If Trump cuts off the U.S. market it would be a major blow to the Quebec company.
Treasury Secretary Scott Bessent warned Carney on Wednesday that his recent public comments against U.S. trade policy could backfire going into the formal review of the U.S.-Mexico-Canada Agreement, the trade deal that protects Canada from the heaviest impacts of Trump’s tariffs.
Carney rejected Bessent’s contention that he had aggressively walked back his comments at the World Economic Forum during a phone call with Trump on Monday.
Carney said he told Trump that he meant what he said in his speech at Davos, and told him Canada plans to diversify away from the United States with a dozen new trade deals.
In Davos at the World Economic Forum last week, Carney condemned economic coercion by great powers on smaller countries without mentioning Trump’s name. The prime minister received widespread praise and attention for his remarks, upstaging Trump at the gathering.
Besides Bombadier, other major aircraft manufacturers in Canada include De Havilland Aircraft of Canada, which makes turboprop planes and aircraft designed for maritime patrols and reconnaissance, and European aerospace giant Airbus. Airbus manufactures its single-aisle A220 commercial planes and helicopters in Canada.
During the Biden administration, the U.S. International Trade Administration touted the interdependence of the U.S. and Canadian aerospace industries and cited a 1980 World Trade Organization agreement that the website of the current U.S. trade representative says “requires signatories to eliminate tariffs on civil aircraft, engines, flight simulators, and related parts and components.”
Canada’s Trade Commissioner Service describes the United States as the largest trading partner for the country’s aerospace and space industries and the destination for a significant portion of exported aircraft, components and space technologies.
Gillies contributed to this report from Toronto. AP writers Lisa Leff and Josh Funk contributed to this report.
President Donald Trump speaks during a cabinet meeting at the White House, Thursday, Jan. 29, 2026, in Washington. (AP Photo/Evan Vucci)
